Analysts See $0.56 EPS for Catalent (CTLT); Abbvie (ABBV) Sellers Increased By 1.48% Their Shorts

August 30, 2017 - By Adrian Mccoy

Analysts expect Catalent Inc (NYSE:CTLT) to report $0.56 EPS on September, 4.They anticipate $0.05 EPS change or 9.80% from last quarter’s $0.51 EPS. CTLT’s profit would be $69.95 million giving it 17.98 P/E if the $0.56 EPS is correct. After having $0.37 EPS previously, Catalent Inc’s analysts see 51.35% EPS growth. The stock increased 13.89% or $4.91 during the last trading session, reaching $40.27. About shares traded. Catalent Inc (NYSE:CTLT) has risen 27.19% since August 30, 2016 and is uptrending. It has outperformed by 10.49% the S&P500.

Abbvie Incorporated (NYSE:ABBV) had an increase of 1.48% in short interest. ABBV’s SI was 21.03 million shares in August as released by FINRA. Its up 1.48% from 20.72 million shares previously. With 5.71 million avg volume, 4 days are for Abbvie Incorporated (NYSE:ABBV)’s short sellers to cover ABBV’s short positions. The SI to Abbvie Incorporated’s float is 1.32%. The stock increased 0.78% or $0.57 during the last trading session, reaching $73.89. About shares traded. AbbVie Inc (NYSE:ABBV) has risen 10.63% since August 30, 2016 and is uptrending. It has underperformed by 6.07% the S&P500.

Among 10 analysts covering Catalent (NYSE:CTLT), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. Catalent has $40.0 highest and $28 lowest target. $34.83’s average target is -13.51% below currents $40.27 stock price. Catalent had 21 analyst reports since September 3, 2015 according to SRatingsIntel. Morgan Stanley downgraded Catalent Inc (NYSE:CTLT) on Thursday, April 21 to “Ewu” rating. The firm has “Overweight” rating given on Thursday, October 20 by KeyBanc Capital Markets. On Monday, August 28 the stock rating was maintained by Jefferies with “Hold”. The firm has “Buy” rating given on Tuesday, August 29 by Bank of America. Bank of America upgraded Catalent Inc (NYSE:CTLT) on Monday, June 20 to “Buy” rating. The stock of Catalent Inc (NYSE:CTLT) earned “Hold” rating by Jefferies on Thursday, September 10. Wells Fargo upgraded the stock to “Outperform” rating in Tuesday, June 21 report. The firm has “Mkt Perform” rating by Raymond James given on Wednesday, December 9. The stock of Catalent Inc (NYSE:CTLT) has “Hold” rating given on Wednesday, November 4 by Deutsche Bank. Goldman Sachs initiated Catalent Inc (NYSE:CTLT) on Thursday, December 1 with “Neutral” rating.

Investors sentiment increased to 2.13 in Q4 2016. Its up 0.71, from 1.42 in 2016Q3. It is positive, as 21 investors sold Catalent Inc shares while 66 reduced holdings. 29 funds opened positions while 69 raised stakes. 126.47 million shares or 0.23% more from 126.18 million shares in 2016Q3 were reported. California Public Employees Retirement Sys holds 204,900 shares or 0.01% of its portfolio. Geode Mngmt Ltd Limited Liability Company holds 902,863 shares or 0.01% of its portfolio. 2.67M are owned by Century Cos. Bernzott Cap Advsr reported 869,560 shares. Barclays Pcl accumulated 0% or 2,978 shares. Menta accumulated 66,304 shares or 0.15% of the stock. Swiss Retail Bank holds 0.01% or 205,070 shares. Tower Research Limited Com (Trc) has 439 shares for 0% of their portfolio. Ubs Asset Management Americas reported 3.87M shares. Perceptive Advisors Ltd has invested 0% of its portfolio in Catalent Inc (NYSE:CTLT). Schwab Charles Inv Mngmt Incorporated invested 0.02% in Catalent Inc (NYSE:CTLT). Creative Planning has 175 shares. Morgan Stanley reported 0% of its portfolio in Catalent Inc (NYSE:CTLT). Connecticut-based Aqr Mngmt Lc has invested 0% in Catalent Inc (NYSE:CTLT). Td Asset Management reported 292,195 shares or 0.01% of all its holdings.

Since March 16, 2017, it had 0 insider purchases, and 2 sales for $2.35 million activity. Chiminski John R also sold $2.11M worth of Catalent Inc (NYSE:CTLT) shares. Downie William had sold 8,262 shares worth $236,293 on Monday, March 20.

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. The company has market cap of $5.03 billion. The Company’s divisions include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. It has a 46.2 P/E ratio. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Investors sentiment increased to 1 in Q4 2016. Its up 0.01, from 0.99 in 2016Q3. It is positive, as 86 investors sold AbbVie Inc shares while 555 reduced holdings. 99 funds opened positions while 531 raised stakes. 1.03 billion shares or 0.70% less from 1.04 billion shares in 2016Q3 were reported. Schaper Benz Wise Inv Counsel Wi holds 0.19% of its portfolio in AbbVie Inc (NYSE:ABBV) for 17,350 shares. Moreover, Of Vermont has 1.52% invested in AbbVie Inc (NYSE:ABBV). New Jersey Better Educational Savings Tru accumulated 16,000 shares. Bollard Grp Ltd Limited Liability Company owns 3,725 shares for 0.02% of their portfolio. 2.93M were reported by Orbimed Advsr Limited Company. Gamble Jones Inv Counsel stated it has 1.55% in AbbVie Inc (NYSE:ABBV). Premier Asset Managment Ltd has invested 0.45% in AbbVie Inc (NYSE:ABBV). 14,023 are owned by Bell National Bank & Trust. Provise Ltd Liability Company has invested 0.27% in AbbVie Inc (NYSE:ABBV). Veritable Limited Partnership invested in 0.21% or 137,438 shares. Wealthtrust Axiom Ltd Liability Co holds 0.1% or 4,292 shares in its portfolio. Founders Capital Management Ltd accumulated 34,317 shares. Raymond James Financial Advsr Inc holds 0.44% of its portfolio in AbbVie Inc (NYSE:ABBV) for 833,464 shares. 27,482 are held by Natl Asset Management. The Ohio-based Winfield Assocs has invested 0.04% in AbbVie Inc (NYSE:ABBV).

Since March 8, 2017, it had 0 insider purchases, and 9 selling transactions for $27.88 million activity. $4.67M worth of AbbVie Inc (NYSE:ABBV) was sold by GONZALEZ RICHARD A. On Thursday, May 4 the insider ALBAN CARLOS sold $2.88 million. 38,300 shares were sold by CHASE WILLIAM J, worth $2.50 million. Shares for $335,068 were sold by Michael Robert A.. $1.47 million worth of AbbVie Inc (NYSE:ABBV) was sold by RICHMOND TIMOTHY J. on Friday, March 10. Schumacher Laura J sold 40,000 shares worth $2.61M.

AbbVie Inc. is a research-based biopharmaceutical company. The company has market cap of $117.79 billion. The Firm is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. It has a 18.05 P/E ratio. The Company’s products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Among 19 analysts covering Abbvie Inc (NYSE:ABBV), 8 have Buy rating, 1 Sell and 10 Hold. Therefore 42% are positive. Abbvie Inc has $95 highest and $6 lowest target. $70.73’s average target is -4.28% below currents $73.89 stock price. Abbvie Inc had 47 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of AbbVie Inc (NYSE:ABBV) has “Hold” rating given on Wednesday, June 7 by Credit Suisse. The stock of AbbVie Inc (NYSE:ABBV) has “Neutral” rating given on Monday, October 31 by Credit Suisse. The firm has “Overweight” rating given on Monday, November 2 by Morgan Stanley. Cowen & Co downgraded the shares of ABBV in report on Monday, June 6 to “Market Perform” rating. The company was maintained on Monday, May 29 by Jefferies. The firm earned “Buy” rating on Tuesday, February 23 by Citigroup. The firm earned “Neutral” rating on Thursday, September 8 by JP Morgan. Barclays Capital downgraded the stock to “Equal-Weight” rating in Tuesday, December 1 report. As per Friday, July 14, the company rating was maintained by Jefferies. The stock of AbbVie Inc (NYSE:ABBV) earned “Hold” rating by BMO Capital Markets on Sunday, July 30.